Emergent BioSolutions Inc (EBS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.60 is considered Undervalued compared with the five-year average of 13.90. The fair price of Emergent BioSolutions Inc (EBS) is between 68.96 to 84.19 according to relative valuation method. Compared to the current price of 8.11 USD , Emergent BioSolutions Inc By Undervalued By 88.24%.

Relative Value

Fair Zone

68.96-84.19

Current Price：8.11

88.24%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Emergent BioSolutions Inc (EBS) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Emergent BioSolutions Inc (EBS) has a current Price-to-Book (P/B) ratio of 1.13. Compared to its 3-year average P/B ratio of 0.62, the current P/B ratio is approximately 81.15% higher. Relative to its 5-year average P/B ratio of 0.96, the current P/B ratio is about 18.04% higher. Emergent BioSolutions Inc (EBS) has a Forward Free Cash Flow (FCF) yield of approximately 0.21%. Compared to its 3-year average FCF yield of -51.17%, the current FCF yield is approximately -100.42% lower. Relative to its 5-year average FCF yield of -28.35%, the current FCF yield is about -100.75% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for EBS competitors is 21.80, providing a benchmark for relative valuation. Emergent BioSolutions Inc Corp (EBS.N) exhibits a P/S ratio of 0.60, which is -97.24% above the industry average. Given its robust revenue growth of -23.63%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of EBS increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of EBS in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is EBS currently overvalued or undervalued?

Emergent BioSolutions Inc (EBS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.60 is considered Undervalued compared with the five-year average of 13.90. The fair price of Emergent BioSolutions Inc (EBS) is between 68.96 to 84.19 according to relative valuation method. Compared to the current price of 8.11 USD, Emergent BioSolutions Inc is Undervalued By 88.24%.

What is Emergent BioSolutions Inc (EBS) fair value?

EBS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Emergent BioSolutions Inc (EBS) is between 68.96 to 84.19 according to relative valuation method.

How does EBS's valuation metrics compare to the industry average?

The average P/S ratio for EBS's competitors is 21.80, providing a benchmark for relative valuation. Emergent BioSolutions Inc Corp (EBS) exhibits a P/S ratio of 0.60, which is -97.24% above the industry average. Given its robust revenue growth of -23.63%, this premium appears unsustainable.

What is the current P/B ratio for Emergent BioSolutions Inc (EBS) as of Mar 02 2026?

As of Mar 02 2026, Emergent BioSolutions Inc (EBS) has a P/B ratio of 1.13. This indicates that the market values EBS at 1.13 times its book value.

What is the current FCF Yield for Emergent BioSolutions Inc (EBS) as of Mar 02 2026?

As of Mar 02 2026, Emergent BioSolutions Inc (EBS) has a FCF Yield of 0.21%. This means that for every dollar of Emergent BioSolutions Inc's market capitalization, the company generates 0.21 cents in free cash flow.

What is the current Forward P/E ratio for Emergent BioSolutions Inc (EBS) as of Mar 02 2026?

As of Mar 02 2026, Emergent BioSolutions Inc (EBS) has a Forward P/E ratio of 4.21. This means the market is willing to pay $4.21 for every dollar of Emergent BioSolutions Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Emergent BioSolutions Inc (EBS) as of Mar 02 2026?

As of Mar 02 2026, Emergent BioSolutions Inc (EBS) has a Forward P/S ratio of 0.60. This means the market is valuing EBS at $0.60 for every dollar of expected revenue over the next 12 months.

EBS Valuation